CARsgen Therapeutics

Focus: CARsgen Therapeutics is a Shanghai-based biotechnology company specializing in CAR-T cell immunotherapy across oncology and autoimmune indications. The company operates as a clinical-stage biotech with a geographically focused presence in China.

Cell Therapy

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Open Jobs

About CARsgen Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow CARsgen Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

38 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Peripheral blood mononuclear cell apheresis

Peripheral Blood Mononuclear Cell

N/A

Clinical Trials (1)

NCT04963959PBMC Collection for Production of UCAR T Cells

N/A

Help build intelligence for CARsgen Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Leading position in CAR-T innovation with 30 active pipeline programs spanning hematologic malignancies, solid tumors, and autoimmune diseases—rare breadth for a single-focus company
Pioneering CAR-T applications in underserved autoimmune indications (SLE, AAV, systemic sclerosis) with limited competitive landscape and high unmet medical need
China-based operations provide access to large patient populations and regulatory pathways with potentially faster clinical development timelines

Watch Out For

No marketed products or revenue generation; company remains entirely dependent on funding and clinical trial progression with no near-term monetization signal
Zero active hiring (0 open roles) and missing critical data on funding status, employee count, and financial position suggest operational dormancy or potential restructuring

Generated by Claude from CARsgen Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

CAR-CD19 T cell

B Cell Lymphoma

N/A

Clinical Trials (1)

NCT03302403Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors

N/A

CT0594CP

Multiple Myeloma

N/A

Clinical Trials (1)

NCT05822037CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

N/A

Zevorcabtagene Autoleucel

Relapsed or Refractory Multiple Myeloma

N/A

Clinical Trials (1)

NCT06825845Long Term Follow-up Observational Study in Patients Treated with Gene-Modified T-Cell Therapy

N/A

Zevorcabtagene Autoleucel

Relapsed/Refractory Multiple Myeloma

N/A

Clinical Trials (1)

NCT06659770A Real-World Observational Study: Zevorcabtagene Autoleucel Injection in Patients with Relapsed/Refractory Multiple Myeloma

N/A

Biological

Relapsed and/or Refractory Multiple Myeloma

N/A

Clinical Trials (2)

NCT07548697A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma

Phase 1

NCT05893693Assess the Safety and Efficacy of CT0594CP Cells in Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

N/A

CAR-BCMA T cells

Refractory or Relapsed Multiple Myeloma

N/A

Clinical Trials (1)

NCT03380039Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma

N/A

CAR-GPC3 T cells

Hepatocellular Carcinoma

N/A

Clinical Trials (1)

NCT03146234CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma

N/A

CT0590 CAR T Cells

Relapsed and/or Refractory Multiple Myeloma

N/A

Clinical Trials (1)

NCT05066022A Study to Access the Safety and Efficacy of CT0590 in Patients With Relapsed and/or Refractory Multiple Myeloma

N/A

CAR-CLD18 T Cells

Advanced Gastric Adenocarcinoma

N/A

Clinical Trials (1)

NCT03159819Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma

N/A

CT0181 Cells

Advanced Hepatocellular Carcinoma

Phase 1

Clinical Trials (1)

NCT04973098Phase I Clinical Trial of CT0181 Cells in the Treatment of Hepatocellular Carcinoma

Phase 1

CAR-CD19 T cells

CD19 Positive Malignant B-cell Leukemia and Lymphoma

Phase 1

Clinical Trials (1)

NCT02933775CD19-redirected Autologous Cells (CAR-CD19 T Cells)

Phase 1

CAR-T cells Infusion chimeric antigen receptor T cells

Plasma Cell Leukemia

Phase 1

Clinical Trials (1)

NCT06988059A Study of CT0596 in Plasma Cell Leukemia

Phase 1

AB011 Injection

Solid Tumor

Phase 1

Clinical Trials (1)

NCT04400383Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors

Phase 1

CAR-GPC3 T Cells

Lung Squamous Cell Carcinoma

Phase 1

Clinical Trials (1)

NCT02876978Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma

Phase 1

CT0180 Cells

Advanced Hepatocellular Carcinoma

Phase 1

Clinical Trials (1)

NCT04756648Phase I Clinical Trial of CT0180 Cells in the Treatment of Hepatocellular Carcinoma

Phase 1

Chimeric antigen receptor modified T cells Infusion

Multiple Myeloma

Phase 1

Clinical Trials (1)

NCT06407947Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma

Phase 1

CAR-GPC3 T Cells

Hepatocellular Carcinoma

Phase 1

Clinical Trials (1)

NCT03884751Chimeric Antigen Receptor T Cells Targeting Glypican-3

Phase 1

CAR-BCMA T cells

Refractory or Relapsed Multiple Myeloma

Phase 1

Clinical Trials (1)

NCT03716856Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma

Phase 1

Experimental: CAR-T cells Infusion

Multiple Myeloma

Phase 1

Clinical Trials (1)

NCT05838131Study of CT071 Injection in RRMM or PPCL

Phase 1

CAR-T cells Infusion

Relapsed/Refractory Multiple Myeloma

Phase 1

Clinical Trials (1)

NCT06718270a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia

Phase 1

CAR-T cells Infusion chimeric antigen receptor T cells

Relapsed/Refractory Plasma Cell Leukemia

Phase 1

Clinical Trials (1)

NCT06730256A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia

Phase 1

CAR-T Therapy

Systemic Lupus Erythematosus (SLE)

Phase 1

Clinical Trials (1)

NCT07339332A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to Severe Refractory Systemic Lupus Erythematosus

Phase 1

CT041 autologous CAR T-cell injection

Pancreatic Cancer

Phase 1

Clinical Trials (1)

NCT05911217A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer

Phase 1

CAR-T Therapy

ANCA Associated Vasculitis (AAV)

Phase 1

Clinical Trials (1)

NCT07033299The Safety, Efficacy, and Cellular Metabolic Kinetics of CT1192 in Treating Patients With Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis

Phase 1

CT011 CAR-GPC3 T Cells Injection

HCC

Phase 1

Clinical Trials (1)

NCT06560827CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection

Phase 1

CAR-T Therapy

SSc-Systemic Sclerosis

Phase 1

Clinical Trials (1)

NCT07355972Safety, Efficacy and Cellular Metabolic Dynamics of CT1195E in Patients With Refractory / Progressive SSC

Phase 1

CAR-CLDN18.2 T-Cells

Advanced Solid Tumor

Phase 1

Clinical Trials (1)

NCT03874897Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.

Phase 1

CAR-T Therapy

Systemic Lupus Erythematosus (SLE)

Phase 1

Clinical Trials (1)

NCT07031713Safety, Efficacy and Cellular Metabolic Dynamics of ct1192 in Patients With Moderate to Severe Refractory SLE

Phase 1

CAR-GPC3 T Cells

Advanced Hepatocellular Carcinoma

Phase 1

Clinical Trials (1)

NCT039802884th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3

Phase 1

CAR-T Therapy

Systemic Lupus Erythematosus (SLE)

Phase 1

Clinical Trials (1)

NCT06822881CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)

Phase 1

CT048 Autologous Injection

Gastric Adenocarcinoma

Phase 1

Clinical Trials (1)

NCT05393986Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors

Phase 1

CT041

Gastric Cancer

Phase 1/2

Clinical Trials (1)

NCT04404595Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers